Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (151-160 of 492) with videos related to

Pageof 50
Sort By:
European Urology Oncology|August 15, 2019
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 TrialsGuru P Sonpavde, Gregory R Pond, Karim Fizazi, et al.
The Lancet. Oncology|July 3, 2020
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemicCrescens Tiu, Rajiv Shinde, Christina Yap, et al.
Plos One|November 17, 2011
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survivalSjoerd T Ligthart, Frank A W Coumans, Gerhardt Attard, et al.
British Journal of Cancer|September 29, 2020
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumoursMalaka Ameratunga, Irene Braña, Petri Bono, et al.
Lancet (London, England)|June 16, 2015
Prostate cancerGerhardt Attard, Chris Parker, Ros A Eeles, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug developmentDaniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Nature Reviews. Clinical Oncology|August 24, 2018
Alternative splicing in prostate cancerAlec Paschalis, Adam Sharp, Jonathan C Welti, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
Investigative Radiology|September 15, 2017
Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular FeaturesRaquel Perez-Lopez, Daniel Nava Rodrigues, Ines Figueiredo, et al.
BJU International|June 26, 2003
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centreB Pamenter, J S De Bono, I L Brown, et al.
Pageof 50

Showing results (151-160 of 492) with videos related to

Sort By:
Pageof 50
European Urology Oncology|August 15, 2019
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 TrialsGuru P Sonpavde, Gregory R Pond, Karim Fizazi, et al.
The Lancet. Oncology|July 3, 2020
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemicCrescens Tiu, Rajiv Shinde, Christina Yap, et al.
Plos One|November 17, 2011
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survivalSjoerd T Ligthart, Frank A W Coumans, Gerhardt Attard, et al.
British Journal of Cancer|September 29, 2020
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumoursMalaka Ameratunga, Irene Braña, Petri Bono, et al.
Lancet (London, England)|June 16, 2015
Prostate cancerGerhardt Attard, Chris Parker, Ros A Eeles, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug developmentDaniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Nature Reviews. Clinical Oncology|August 24, 2018
Alternative splicing in prostate cancerAlec Paschalis, Adam Sharp, Jonathan C Welti, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
Investigative Radiology|September 15, 2017
Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular FeaturesRaquel Perez-Lopez, Daniel Nava Rodrigues, Ines Figueiredo, et al.
BJU International|June 26, 2003
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centreB Pamenter, J S De Bono, I L Brown, et al.
Pageof 50